About this Journal Submit a Manuscript Table of Contents
ISRN Rheumatology
Volume 2012 (2012), Article ID 765380, 8 pages
http://dx.doi.org/10.5402/2012/765380
Clinical Study

High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?

Division of Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA

Received 8 September 2011; Accepted 3 October 2011

Academic Editor: C. J. Chen

Copyright © 2012 Sukesh Sukumaran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [11 citations]

The following is the list of published articles that have cited the current article.

  • Adriano Magli, Raimondo Forte, Pasqualina Navarro, Giustina Russo, Francesca Orlando, Loredana Latanza, and Maria Alessio, “Adalimumab for juvenile idiopathic arthritis-associated uveitis,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 6, pp. 1601–1606, 2013. View at Publisher · View at Google Scholar
  • Matthew L. Stoll, and Randy Q. Cron, “Treatment of Juvenile Idiopathic Arthritis in the Biologic Age,” Rheumatic Disease Clinics of North America, vol. 39, no. 4, pp. 751–+, 2013. View at Publisher · View at Google Scholar
  • Sibel Kadayifcilar, and Seza Ozen, “Rheumatic Inflammatory Eye Diseases of Childhood,” Rheumatic Disease Clinics of North America, vol. 39, no. 4, pp. 801–+, 2013. View at Publisher · View at Google Scholar
  • Ajay Tambralli, Timothy Beukelman, Peter Weiser, Thomas Prescott Atkinson, Randy Quentin Cron, and Matthew Laurence Stoll, “High Doses of Infliximab in the Management of Juvenile Idiopathic Arthritis,” Journal of Rheumatology, vol. 40, no. 10, pp. 1749–1755, 2013. View at Publisher · View at Google Scholar
  • Femke H. M. Prince, and Daniel H. Solomon, “Dosing of Biologics in Juvenile Idiopathic Arthritis: Is the Sky the Limit?,” Journal of Rheumatology, vol. 40, no. 10, pp. 1643–1645, 2013. View at Publisher · View at Google Scholar
  • Maria Pia Paroli, Alessandro Abbouda, Irene Abicca, Alfredo Sapìa, and Marino Paroli, “Biological agents in the treatment of uveitis,” Advances in Bioscience and Biotechnology, vol. 04, no. 08, pp. 64–72, 2013. View at Publisher · View at Google Scholar
  • Gabriele Simonini, Katie Druce, Rolando Cimaz, Gary J. Macfarlane, and Gareth T. Jones, “Current Evidence of Anti-Tumor Necrosis Factor alpha Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach of Individual Drugs,” Arthritis Care & Research, vol. 66, no. 7, pp. 1073–1084, 2014. View at Publisher · View at Google Scholar
  • Rosa Bou, Estíbaliz Iglesias, and Jordi Antón, “Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis,” Current Rheumatology Reports, vol. 16, no. 8, 2014. View at Publisher · View at Google Scholar
  • Randy Q. Cron, “Treatment of juvenile idiopathic arthritis: a revolution in care,” Pediatric Rheumatology, vol. 12, 2014. View at Publisher · View at Google Scholar
  • Jonathan N. Kruh, Paul Yang, Ana M. Suelves, and C. Stephen Foster, “Infliximab for the Treatment of Refractory Noninfectious Uveitis A Study of 88 Patients with Long-term Follow-up,” Ophthalmology, vol. 121, no. 1, pp. 358–364, 2014. View at Publisher · View at Google Scholar
  • Melissa A. Lerman, and C. Egla Rabinovich, “The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis,” Pediatric Drugs, 2015. View at Publisher · View at Google Scholar